HomeCompareITCI vs ADC

ITCI vs ADC: Dividend Comparison 2026

ITCI yields 1.52% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $157.1K in total portfolio value
10 years
ITCI
ITCI
● Live price
1.52%
Share price
$131.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$167.32
Full ITCI calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — ITCI vs ADC

📍 ADC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITCIADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITCI + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITCI pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITCI
Annual income on $10K today (after 15% tax)
$128.91/yr
After 10yr DRIP, annual income (after tax)
$142.22/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,535.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITCI + ADC for your $10,000?

ITCI: 50%ADC: 50%
100% ADC50/50100% ITCI
Portfolio after 10yr
$100.4K
Annual income
$40,482.31/yr
Blended yield
40.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ITCI
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$98.50
-25.3% upside vs current
Range: $70.00 — $132.00
Altman Z
38.0
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITCI buys
0
ADC buys
0
No recent congressional trades found for ITCI or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITCIADC
Forward yield1.52%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$21.9K$178.9K
Annual income after 10y$167.32$80,797.29
Total dividends collected$1.6K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$98.50$81.06

Year-by-year: ITCI vs ADC ($10,000, DRIP)

YearITCI PortfolioITCI Income/yrADC PortfolioADC Income/yrGap
1← crossover$10,852$151.66$10,990$580.36$138.00ADC
2$11,765$153.81$12,301$860.26$536.00ADC
3$12,745$155.85$14,104$1,298.62$1.4KADC
4$13,794$157.78$16,691$2,008.16$2.9KADC
5$14,920$159.61$20,580$3,205.09$5.7KADC
6$16,125$161.33$26,754$5,330.02$10.6KADC
7$17,417$162.96$37,196$9,345.14$19.8KADC
8$18,801$164.50$56,244$17,523.09$37.4KADC
9$20,283$165.95$94,286$35,736.21$74.0KADC
10$21,870$167.32$178,949$80,797.29$157.1KADC

ITCI vs ADC: Complete Analysis 2026

ITCIStock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Full ITCI Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ITCI vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITCI vs SCHDITCI vs JEPIITCI vs OITCI vs KOITCI vs MAINITCI vs NNNITCI vs EPRTITCI vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.